Pulmonary fibrosis is a deadly disease in which the lungs become thickened and scarred, gradually losing their ability to ...
More than 10 years after bringing one of the first idiopathic pulmonary fibrosis (IPF) drugs to market, Boehringer Ingelheim ...
For years, MASH was where drug development dreams went to die. | After Rezdiffra’s approval and Wegovy’s label expansion, ...
The FDA granted approval to nerandomilast, now Jascayd, for treating adults with idiopathic pulmonary fibrosis, marking the ...
Clinical Trials Arena on MSN
Clarametyx completes enrolment in cystic fibrosis trial
Clarametyx has concluded subject enrolment in its Phase Ib/IIa study of CMTX-101, an immune-enhancing antibody therapy being ...
The US Food and Drug Administration (FDA) has approved Boehringer Ingelheim Jascayd (nerandomilast) tablets to treat ...
Brensocatib effectively reduces NSP activity in bronchiectasis patients, with greater reductions observed in the 25-mg dose group compared to the 10-mg group.
Jascayd targets the enzyme PDE4B, which plays a role in the inflammatory process. The new therapy is able to affect both ...
Maren Denison, third-year student at the University of Iowa, was in sixth grade when she found out her lung function had ...
Derek Hill’s parents were told he might not reach his 18th birthday, but he’s still here at 28, helping coach Keller Central ...
The U.S. Food and Drug Administration has approved Jascayd (nerandomilast) tablets to treat idiopathic pulmonary fibrosis ...
FDA approves Jascayd, the first new treatment for idiopathic pulmonary fibrosis in over a decade, significantly reducing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback